EPIRUBICIN 50MG INJECTION
Injection is used in the treatment of various types of cancers of blood, breast, stomach, lung, ovaries and soft tissues. It also helps to prevent the recurrence of bladder cancer after surgery.
Epirubicin 50 mg Injection is a prescription chemotherapy medicine used as part of specific cancer treatment regimens, including certain breast cancer regimens. It belongs to the anthracycline class of cytotoxic medicines and works by interfering with cancer cell DNA, helping to inhibit cancer cell growth.
Epirubicin 50 mg Injection contains epirubicin hydrochloride, an anthracycline medicine used in chemotherapy. It is administered intravenously by qualified healthcare professionals as part of a cancer treatment plan.
The medicine interferes with processes needed for cancer cells to grow and multiply. Its use depends on the cancer type, treatment regimen, previous therapy and the patient's overall health. The exact approved indications may vary by country and product.
Epirubicin 50 mg Injection may be prescribed to:
Treat certain cancers as part of a combination chemotherapy regimen.
Form part of adjuvant chemotherapy for selected patients with breast cancer following surgery, where indicated.
Treat other cancers when epirubicin is included in an appropriate specialist-directed treatment protocol approved for the relevant market.
The appropriate treatment and dose must be determined by an oncologist based on the diagnosis, treatment protocol, body surface area, organ function and previous chemotherapy.
Epirubicin interferes with DNA, the genetic material cancer cells need to grow and divide. It also inhibits an enzyme called topoisomerase II, which is involved in DNA replication, and can generate substances that damage cellular structures.
These actions help prevent cancer cells from multiplying and may lead to cell death. The treatment response and timing vary according to the cancer type and the chemotherapy regimen.
Take Epirubicin exactly as prescribed by your healthcare professional. This medicine must be administered by qualified healthcare professionals experienced in cancer chemotherapy.
Administration: Epirubicin is given intravenously, usually as part of a planned chemotherapy regimen. It must not be injected into muscle or under the skin.
Dosage and timing: The dose, infusion schedule and number of treatment cycles depend on the cancer being treated, the regimen and individual clinical factors.
Monitoring: Blood counts, liver function and heart function may be assessed before and during treatment.
Missed appointments: Contact your oncology team promptly if you miss a scheduled treatment. Do not attempt to adjust the treatment schedule yourself.
Treatment changes: Do not delay, discontinue or change chemotherapy without guidance from your oncology team.
If the medicine leaks outside the vein during administration, it can cause severe tissue damage. Tell the healthcare professional immediately if you experience burning, pain or swelling around the infusion site.
Tell your oncologist or pharmacist about your medical history and all medicines, supplements and herbal products you use before starting epirubicin.
Particular caution is required if you have:
Heart disease: Epirubicin can damage the heart muscle and may cause heart failure. The risk increases with cumulative exposure and certain other cancer treatments.
Low blood cell counts: The medicine can suppress bone marrow function, increasing the risk of infection, anaemia and bleeding.
Liver problems: Impaired liver function may affect how the medicine is processed and may require treatment adjustments.
Previous chemotherapy or radiotherapy: Earlier treatment with anthracyclines or other treatments affecting the heart or bone marrow may increase certain risks.
Previous allergic reactions: Tell your healthcare professional about any reaction to epirubicin or related anthracycline medicines.
Important medicine interactions: Other chemotherapy medicines, treatments that may damage the heart, medicines that affect bone marrow function and certain drugs that influence liver enzymes may alter the risks or effects of epirubicin. Live vaccines may also be unsuitable during immunosuppressive chemotherapy.
Your oncology team should review all medicines and potential interactions before treatment begins.
Pregnancy: Epirubicin may cause harm to an unborn baby and is generally avoided during pregnancy unless a specialist determines that treatment is necessary after carefully assessing the risks and benefits. Tell your oncologist if you are pregnant, think you may be pregnant or are planning a pregnancy. Effective contraception and advice about future fertility may be needed during treatment.
Breastfeeding: Breastfeeding is generally not recommended during epirubicin treatment because of the potential for serious harm to the infant. Ask your oncology team when breastfeeding can be stopped or resumed, based on the treatment plan and official product information.
Recommendations may vary according to the specific product and local prescribing guidance.
Like all medicines, Epirubicin can cause side effects, although not everyone experiences them.
Common or recognised side effects may include:
Nausea and vomiting.
Hair loss.
Mouth sores or inflammation of the mouth.
Reduced blood cell counts.
Fatigue.
Red or pink urine for a short period after administration.
Seek urgent medical attention for fever or signs of infection, unusual bleeding or bruising, chest pain, shortness of breath, swelling of the legs, severe allergic symptoms or pain and swelling around the injection site. These may indicate serious complications, including infection, heart problems or tissue damage.
This is not a complete list of side effects or warnings. Please refer to the product packaging and patient information leaflet supplied with your medicine for complete information and speak with your doctor or pharmacist if you have concerns.
Store Epirubicin according to the instructions shown on the original product packaging.
Keep the medicine in its original packaging until required for use.
Some presentations require refrigerated storage and protection from light; follow the specific product label.
Do not freeze the medicine unless the official product instructions explicitly permit it.
Keep out of reach of children.
Do not use the medicine after its expiry date.
Epirubicin is a cytotoxic medicine and requires appropriate handling and disposal by trained healthcare professionals. Storage conditions may differ by manufacturer and formulation.
Epirubicin is a chemotherapy medicine used in selected cancer treatment regimens, including certain breast cancer regimens. Its use depends on the cancer diagnosis and the treatment protocol recommended by an oncologist.
Epirubicin is administered into a vein by qualified healthcare professionals experienced in chemotherapy. The dose and schedule are determined by the oncology team.
The response depends on the cancer type, treatment combination and individual circumstances. Your oncology team may assess the response through clinical examinations, blood tests or imaging at appropriate intervals.
Epirubicin requires specialist handling and intravenous administration in an appropriate healthcare setting. It should not be self-administered or handled outside the arrangements made by the treating oncology team.
Yes, hair loss is a recognised side effect of epirubicin, although its severity varies between patients and treatment regimens. Your oncology team can explain what to expect with your specific chemotherapy plan.
Yes. Epirubicin can damage the heart muscle, and the risk may increase with higher cumulative doses or certain other cancer treatments. Heart function may be assessed before and during treatment, with further monitoring when indicated.
Contact your oncology team urgently if you develop a fever, chills or other signs of infection. Epirubicin can lower white blood cell counts, which may reduce the body's ability to fight infections.